Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis

Background: Interleukin-6 (IL-6) is known to be detrimental in coronavirus disease 2019 (COVID-19) because of its involvement in driving cytokine storm. This systematic review and meta-analysis aimed to assess the safety and efficacy of anti-IL-6 signaling (anti-IL6/IL-6R/JAK) agents on COVID-19 bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Qi, Guo, Mingyue, Zheng, Yue, Zhang, Ying, De, Yanshan, Xu, Changchang, Zhang, Lin, Sun, Ruru, Lv, Ying, Liang, Yan, Xu, Feng, Pang, Jiaojiao, Chen, Yuguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769953/
https://www.ncbi.nlm.nih.gov/pubmed/33384605
http://dx.doi.org/10.3389/fphar.2020.615972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769953/
https://www.ncbi.nlm.nih.gov/pubmed/33384605
http://dx.doi.org/10.3389/fphar.2020.615972

Ejemplares similares